Randomized phase II trial of S-1 and cisplatin versus gemcitabine and cisplatin in patients with advanced biliary tract adenocarcinoma

Acta Oncologica
Myoung Joo KangMyung-Hwan Kim

Abstract

We evaluated the efficacy and safety of a combination of S-1 and cisplatin (SP) versus gemcitabine and cisplatin (GP) as first-line therapy for advanced biliary tract adenocarcinoma (ABTA). Patients were randomized to receive cisplatin (60 mg/m(2) intravenously [IV] on Day 1) plus S-1 (40 mg/m(2) bid orally on Days 1-14) or gemcitabine (1000 mg/m(2) IV at 10 mg/m(2)/min on Days 1 and 8) every three weeks. The primary end point was six-month progression-free survival (PFS). Of 96 eligible patients, 49 were randomized to GP and 47 to SP. At a median follow-up time of 14.2 months, the six-month PFS rates were 43.8% and 34.7%, respectively [unadjusted HR (GP/SP) =0.85, 95% CI 0.52-1.36]. The median OS values in the GP and SP groups were 10.1 months and 9.9 months, respectively [unadjusted HR (GP/SP) =0.72, 95% CI 0.45-1.17]. Grade 3-4 toxicities in the GP and SP groups included neutropenia (49.0% vs. 31.8%), anemia (22.4% vs. 2.3%), thrombocytopenia (22.4% vs. 4.5%), and asthenia (4.1% vs. 2.1%). Both GP and SP has comparable efficacy with favorable safety profile as first-line treatment for ABTA. (ClinicalTrials.gov number NCT 01375972).

References

Mar 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J L AbbruzzeseM N Raber
Jul 29, 1998·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M DucreuxJ P Armand
Oct 28, 1999·The New England Journal of Medicine·P C de GroenD M Nagorney
Jul 30, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Margaret TemperoJames Abbruzzese
Oct 27, 2004·British Journal of Cancer·H UenoC Morizane
Jan 26, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S ThongprasertS Moonprakan
Sep 6, 2005·Cancer Chemotherapy and Pharmacology·Takuji OkusakaToshio Tsuyuguchi
Jan 24, 2007·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun
Feb 28, 2007·British Journal of Cancer·F Eckel, R M Schmid
Sep 12, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·Y J KimY J Bang
Oct 19, 2007·Japanese Journal of Clinical Oncology·Naohiro YonemotoTosiya Sato
Jan 25, 2008·Cancer Chemotherapy and Pharmacology·Junji FuruseAkihiro Funakoshi
May 2, 2008·The Oncologist·Aram F Hezel, Andrew X Zhu
Apr 9, 2010·The New England Journal of Medicine·Juan ValleUNKNOWN ABC-02 Trial Investigators
Apr 1, 2004·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Hai-Rim ShinUNKNOWN 139 KCCR-affiliated Hospitals

❮ Previous
Next ❯

Citations

Jun 22, 2013·Critical Reviews in Oncology/hematology·Stefano CeredaMichele Reni
May 21, 2015·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Joon Oh ParkHo Yeong Lim
Nov 26, 2014·Cancer Chemotherapy and Pharmacology·Tadashi UwagawaKatsuhiko Yanaga
Jan 24, 2017·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Dae-Won LeeYung-Jue Bang
Apr 7, 2018·The Cochrane Database of Systematic Reviews·Omar Abdel-RahmanHesham Elhalawani
Mar 21, 2019·Liver International : Official Journal of the International Association for the Study of the Liver·Jorge AdevaJuan W Valle
Sep 7, 2013·The Korean Journal of Internal Medicine·Takashi SasakiKazuhiko Koike
Dec 31, 2014·World Journal of Gastroenterology : WJG·Heng LiuLun-Gen Lu
Jul 25, 2021·Journal of Clinical Medicine·Takashi SasakiNaoki Sasahira

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.